Silexion Therapeutics Corp
SLXN Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2023–FY2025
Last close · Oct 23, 2026
$0.19
14.3%What Silexion Therapeutics Corp does
No business description yet.
- Legal name
- Silexion Therapeutics Corp
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Accession · CIK
- 0001178913-26-000953
0002022416
Revenue and margins
Silexion Therapeutics Corp had — of revenue in fiscal 2025.
Net income and earnings per share
From fiscal 2023 to 2025, diluted EPS grew −55.0% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$10.8M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Silexion Therapeutics Corp returned — to shareholders in fiscal 2025. The diluted share count rose 3,095.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Silexion Therapeutics Corp can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $4.6M | $1.2M | $6.0M |
| Current ratio | 2.3x | 0.6x | 2.4x |
| Quick ratio | 2.3x | 0.6x | 2.4x |
| Total assets | $5.3M | $2.9M | $7.2M |
| Total liabilities | $2.3M | $6.9M | $4.6M |
| Shareholders' equity | −$15.5M | −$4.0M | $2.6M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✕ | ✓ |
| Share count didn't rise | — | ✓ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −11.0% | −200.1% | −21.7% |
| Altman Z'' | −26.35 | −82.29 | −31.64 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $3.7M | $5.8M | $7.1M |
| Operating income | −$4.7M | −$12.6M | −$11.6M |
| Pretax income | −$5.1M | −$16.5M | −$11.9M |
| Income tax | $0.0M | $0.0M | $0.0M |
| Net income | −$5.1M | −$16.5M | −$11.9M |
| Net income to common | $4.9M | $16.4M | $11.9M |
| Diluted EPS | $44.23 | $394.94 | $8.96 |
| Diluted shares | 0.00B | 0.00B | 0.00B |
| Cash flow | |||
| Cash from operations | −$4.5M | −$8.4M | −$10.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$4.5M | −$8.4M | −$10.8M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $0.1M | $5.9M | $0.1M |
| Balance sheet | |||
| Cash and short-term investments | $4.6M | $1.2M | $6.0M |
| Current assets | $5.0M | $2.3M | $6.6M |
| Current liabilities | $2.2M | $3.5M | $2.8M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M |
| Total assets | $5.3M | $2.9M | $7.2M |
| Total liabilities | $2.3M | $6.9M | $4.6M |
| Shareholders' equity | −$15.5M | −$4.0M | $2.6M |
| Returns | |||
| Return on capital employed | −153.0% | 1,904.7% | −261.0% |
| Return on assets | −97.2% | −406.9% | −236.4% |
| Return on tangible equity | — | — | 457.6% |
| Growth | |||
| EPS growth | — | 792.9% | −97.7% |
| Share count change | — | −62.8% | 3,095.9% |
| Financial health | |||
| Current ratio | 2.3x | 0.6x | 2.4x |
| Quick ratio | 2.3x | 0.6x | 2.4x |
| Quality scores | |||
| Altman Z'' | −26.3 | −82.3 | −31.6 |
| Accruals ratio | −11.0% | −200.1% | −21.7% |
Source: SEC EDGAR XBRL filings (CIK 0002022416). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.